Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study
ConclusionNeoadjuvant axitinib in cT2 ccRCC is feasible and, even with a modest decrease in size, allowed a tumour shrinkage<7 cm in 12 cases; however, PN procedures remained complex, requiring surgical expertise with possible morbidity.
Source: BJU International - Category: Urology & Nephrology Authors: Cedric Lebacle,
Karim Bensalah,
Jean ‐Christophe Bernhard,
Laurence Albiges,
Brigitte Laguerre,
Marine Gross‐Goupil,
Herve Baumert,
Herve Lang,
Thibault Tricard,
Brigitte Duclos,
Armelle Arnoux,
Celine Piedvache,
Jean‐Jacques Patard,
Be Tags: Original Article Source Type: research
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Neoadjuvant Therapy | Nephrectomy | Renal Cell Carcinoma | Study